While we have developed new treatments for type 2 diabetes and obesity, such as glucagon-like peptide-1 (GLP-1) receptor agonists, their efficacy and accessibility are still limited
We welcome original research articles, review articles, and communications that focus on the dysregulation of immune pathways, cytokine networks, and genetic and epigenetic factors contributing to inflammation and tissue damage in rheumatic diseases
While the potential benefits are impressive, GLP-1 medications aren't appropriate for everyone with sleep apnea
Works Synergistically with Other Actives In formulation, GHK-Cu can be paired with Hyaluronic Acid, Niacinamide, or Panthenol for enhanced hydration, barrier support, and regeneration